Lindsay E. Clegg

817 total citations
25 papers, 425 citations indexed

About

Lindsay E. Clegg is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Lindsay E. Clegg has authored 25 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Oncology. Recurrent topics in Lindsay E. Clegg's work include Angiogenesis and VEGF in Cancer (8 papers), Diabetes Treatment and Management (7 papers) and Diabetes Management and Research (5 papers). Lindsay E. Clegg is often cited by papers focused on Angiogenesis and VEGF in Cancer (8 papers), Diabetes Treatment and Management (7 papers) and Diabetes Management and Research (5 papers). Lindsay E. Clegg collaborates with scholars based in United States, United Kingdom and Sweden. Lindsay E. Clegg's co-authors include Feilim Mac Gabhann, Jeffrey A. Hubbell, Mikaël M. Martino, Priscilla S. Briquez, Robert C. Penland, David W. Boulton, Rury R. Holman, Hiddo J.L. Heerspink, Robert J. Mentz and Adrian F. Hernandez and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Diabetes Care.

In The Last Decade

Lindsay E. Clegg

22 papers receiving 421 citations

Peers

Lindsay E. Clegg
David M. Salvay United States
Serena Barachini Italy
Francesca Marano Italy
Ronald Carnemolla United States
Grace Liang United States
Linsey E. Lindley United States
Hsin‐I Hung United States
Maria Grupillo Italy
Xiang Xiao China
Sandra M. Ayuk South Africa
David M. Salvay United States
Lindsay E. Clegg
Citations per year, relative to Lindsay E. Clegg Lindsay E. Clegg (= 1×) peers David M. Salvay

Countries citing papers authored by Lindsay E. Clegg

Since Specialization
Citations

This map shows the geographic impact of Lindsay E. Clegg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsay E. Clegg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsay E. Clegg more than expected).

Fields of papers citing papers by Lindsay E. Clegg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsay E. Clegg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsay E. Clegg. The network helps show where Lindsay E. Clegg may publish in the future.

Co-authorship network of co-authors of Lindsay E. Clegg

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsay E. Clegg. A scholar is included among the top collaborators of Lindsay E. Clegg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsay E. Clegg. Lindsay E. Clegg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clegg, Lindsay E., et al.. (2026). Digital twins for accelerating drug discovery and development: opportunities and challenges. Drug Discovery Today. 31(2). 104617–104617.
2.
3.
Wilkins, Deidre, Ulrika Wählby Hamrén, Lindsay E. Clegg, et al.. (2024). RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. PEDIATRICS. 154(5). 12 indexed citations
4.
Clegg, Lindsay E., Samuel A. Matthews, Tom White, et al.. (2024). Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitroIC50 values predict SARS‐CoV‐2 neutralising antibody titres. Clinical & Translational Immunology. 13(6). e1517–e1517. 2 indexed citations
5.
Clegg, Lindsay E., et al.. (2024). Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants. The Journal of Clinical Pharmacology. 64(5). 555–567. 4 indexed citations
6.
Clegg, Lindsay E., Henning Schmidt, Weifeng Tang, et al.. (2024). Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19. Antimicrobial Agents and Chemotherapy. 68(5). e0158723–e0158723. 3 indexed citations
7.
Clegg, Lindsay E., Lulu Chu, Mats Någård, David W. Boulton, & Robert C. Penland. (2023). Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study. CPT Pharmacometrics & Systems Pharmacology. 13(2). 296–307. 3 indexed citations
8.
9.
Aoki, Yasunori, Bengt Hamrén, Lindsay E. Clegg, et al.. (2021). Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). SHILAP Revista de lepidopterología. 1 indexed citations
10.
Clegg, Lindsay E., Yankang Jing, Robert C. Penland, et al.. (2021). Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials. Diabetes Obesity and Metabolism. 23(5). 1101–1110. 5 indexed citations
11.
Aoki, Yasunori, Bengt Hamrén, Lindsay E. Clegg, et al.. (2021). Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). PLoS ONE. 16(11). e0259372–e0259372. 7 indexed citations
12.
Clegg, Lindsay E., Robert C. Penland, David W. Boulton, et al.. (2020). Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes Obesity and Metabolism. 22(12). 2493–2498. 25 indexed citations
13.
Clegg, Lindsay E., Adrian F. Hernandez, George L. Bakris, et al.. (2020). Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obesity and Metabolism. 22(5). 798–806. 12 indexed citations
14.
Clegg, Lindsay E., Robert C. Penland, David W. Boulton, et al.. (2019). Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology. 18(1). 138–138. 57 indexed citations
15.
16.
Clegg, Lindsay E. & Feilim Mac Gabhann. (2017). A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands. PLoS Computational Biology. 13(3). e1005445–e1005445. 23 indexed citations
17.
Clegg, Lindsay E., Vijay C. Ganta, Brian H. Annex, & Feilim Mac Gabhann. (2017). Systems Pharmacology of VEGF165b in Peripheral Artery Disease. CPT Pharmacometrics & Systems Pharmacology. 6(12). 833–844. 14 indexed citations
18.
Clegg, Lindsay E. & Feilim Mac Gabhann. (2015). Molecular mechanism matters: Benefits of mechanistic computational models for drug development. Pharmacological Research. 99. 149–154. 26 indexed citations
19.
Clegg, Lindsay E. & Feilim Mac Gabhann. (2015). Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model. PLoS Computational Biology. 11(6). e1004158–e1004158. 41 indexed citations
20.
Clegg, Lindsay E. & Feilim Mac Gabhann. (2015). Systems biology of the microvasculature. Integrative Biology. 7(5). 498–512. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David M. Salvay Breakdown of academic impact, for papers by Serena Barachini Breakdown of academic impact, for papers by Francesca Marano Breakdown of academic impact, for papers by Ronald Carnemolla Breakdown of academic impact, for papers by Grace Liang Breakdown of academic impact, for papers by Linsey E. Lindley Breakdown of academic impact, for papers by Hsin‐I Hung Breakdown of academic impact, for papers by Maria Grupillo Breakdown of academic impact, for papers by Xiang Xiao Breakdown of academic impact, for papers by Sandra M. Ayuk
Rankless by CCL
2026